Vera Therapeutics (VERA) Stock; Surges 7% as FDA Clears Trutakna for Rare Kidney Disease

TLDRs;

• Vera Therapeutics shares climbed more than 7% after the FDA granted accelerated approval to Trutakna for primary IgA nephropathy patients.
• Trutakna is the first approved therapy designed to target both BAFF and APRIL, key immune pathways linked to IgA nephropathy.
• Investors are now looking toward Q3 2026 ORIGIN 3 kidney function data, which could determine the drug’s path to full approval.
• Analysts remain optimistic on Vera despite growing competition, with most maintaining bullish ratings and price targets well above current levels.

Vera Therapeutics (NASDAQ: VERA) shares rallied more than 7% on Tuesday after the U.S. Food and Drug Administration (FDA) granted accelerated approval to Trutakna, the company’s treatment for adults with primary IgA nephropathy (IgAN) who are at risk of disease progression.

The stock closed at $42.96, gaining 7.05% during the trading session as investors welcomed the long-awaited regulatory decision. Trading activity also surged, with approximately 4.43 million shares changing hands, well above the company’s typical daily average.

The approval removes one of the largest regulatory hurdles facing Vera Therapeutics, but it also marks the beginning of a new phase for the biotechnology company. Investors are now shifting their attention from regulatory uncertainty to commercial execution and upcoming clinical data that could determine the drug’s long-term prospects.

Based on the company’s outstanding shares, Tuesday’s rally added roughly $203 million to Vera’s market value, bringing its overall valuation to approximately $3.08 billion.

First-In-Class Kidney Therapy

Trutakna received accelerated approval for reducing proteinuria, a condition involving excessive protein leakage into the urine, in adults diagnosed with primary IgA nephropathy, a rare autoimmune kidney disease that can gradually lead to permanent kidney damage and, in severe cases, kidney failure.

Vera Therapeutics, Inc., VERA

Unlike existing therapies, Trutakna is the first approved medicine to simultaneously target both BAFF and APRIL, two immune signaling proteins believed to play a central role in the production of abnormal IgA antibodies that contribute to the disease.

The FDA‘s accelerated approval, however, is based primarily on reductions in proteinuria rather than proven long-term preservation of kidney function. As a result, the drug’s continued approval will depend on confirmatory clinical evidence demonstrating that it can meaningfully delay kidney decline.

Q3 Data Remains Critical

Although the regulatory milestone was widely expected, many analysts believe the next major catalyst for Vera shares will arrive later this year.

The company’s ongoing ORIGIN 3 Phase 3 study remains blinded and placebo-controlled, with results evaluating kidney function through estimated glomerular filtration rate (eGFR) expected during the third quarter of 2026.

Those findings will likely determine whether Trutakna can secure traditional FDA approval beyond its accelerated authorization.

The FDA approved a new medicine from the biotech company Vera Therapeutics for patients with a type of chronic autoimmune kidney disease. https://t.co/b4XsrsCS6i

— STAT (@statnews) July 7, 2026

Earlier interim data from the ORIGIN 3 study were encouraging. Vera reported that patients receiving Trutakna experienced a 46% reduction in proteinuria from baseline and a 42% improvement compared with placebo after 36 weeks of treatment.

The company said the most frequently reported side effects included infections and injection-site reactions, which were generally consistent with expectations for therapies targeting immune pathways.

Analysts Stay Bullish Despite Competition

Wall Street remains optimistic following the FDA approval, with 12 of 13 analysts maintaining Buy ratings on Vera Therapeutics. BofA Securities reaffirmed its $70 price target, while H.C. Wainwright kept a more bullish $110 target despite the stock still trading about 23% below its 52-week high.

Vera now faces established rivals including Novartis’ Fabhalta, Travere’s Filspari, Otsuka’s Voyxact, and Calliditas’ Tarpeyo. Backed by $596.8 million in cash, the company is well-funded for its U.S. launch, but investors are now focused on commercial execution and the pivotal Q3 kidney function data.